Exelixis, Merck Strike Deal to Develop Zanzalintinib for Multiple Types of Cancer

Posted on by admin

As part of the collaboration, Exelixis and Merck will evaluate zanzalintinib in combination with Keytruda for head and neck cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *